For people with advanced thyroid cancer that has stopped responding to standard treatment, the path forward can feel uncertain. A new review of the latest research suggests that molecular profiling, or looking at the genetic makeup of a tumor, could help doctors choose more effective targeted therapies.
The review looked at a range of targeted drugs, including BRAF/MEK inhibitors, RET/TRK inhibitors, and VEGFR-targeted multikinase inhibitors like lenvatinib. It also covered newer approaches like redifferentiation therapies and immune checkpoint inhibitors. The idea is to match the drug to the specific genetic change driving a person's cancer.
Because this is a review of existing studies, not a new clinical trial, the evidence is based on what has already been published. The authors stress that early and comprehensive genomic profiling, including fusion detection, is essential to optimize treatment and address resistance. This means testing tumors for a wide range of genetic alterations, not just the most common ones.
While the review does not provide new data on safety or survival, it highlights a growing consensus: personalized treatment based on tumor genetics is becoming a cornerstone of care for advanced thyroid cancer. For patients and doctors, this reinforces the importance of genetic testing to explore all possible options.
